Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

This Phase 1 study tests a new drug called HSK42360 for children and teenagers with recurrent malignant brain tumors (such as gliomas) that have a specific genetic mutation called BRAF V600. This mutation is found in a subset of brain tumors and makes them potentially vulnerable to targeted therapy. **You may be eligible if...** - You are between 6 and 17 years old - You have a confirmed recurrent malignant brain tumor with a BRAF V600 mutation - Your tumor has failed to respond to or has progressed after standard treatment - You have adequate kidney, liver, and blood function - Your overall performance is relatively good (Karnofsky/Lansky score above 60) **You may NOT be eligible if...** - You have an NF1 gene mutation - You have had another malignant tumor within the past 2 years (some skin cancers may be exempt) - You have active, uncontrolled brain swelling or frequent seizures Talk to your doctor to see if this trial is right for you.